# Golden Patient Profile: Maria Rodriguez - Breast Cancer Patient

## Patient Overview

- **Story Arc:** Breast lump discovery â†’ Diagnosis & staging â†’ Surgery â†’ Chemotherapy â†’ Radiation â†’ Adjuvant endocrine therapy â†’ Surveillance
  > "Patient is a 58-year-old female with Stage IIB ER+/PR+/HER2- invasive ductal carcinoma of the right breast. Demonstrates comprehensive oncology testing with tumor marker trending (CA 15-3: 75â†’12 U/mL, CEA: 8.5â†’2.1 ng/mL), serial imaging (8 mammograms, 6 CT scans, 4 bone scans), surgical intervention, chemotherapy, and endocrine therapy. Excellent test case for cancer queries, treatment timelines, and survivorship care."

---

## Timeline: The Clinical Progression

### Phase 1: Initial Diagnosis (Week 0) - Discovery of Breast Mass ðŸ’¥

**The Story:** 58-year-old woman discovers a firm, non-mobile mass in right breast during self-exam. Presents to primary care with palpable 2.5cm mass in upper outer quadrant. No family history of breast cancer.

#### Diagnostic Workup:

**Vital Signs:**

- Weight: 68-72 kg
- BMI: 25.8-27.2 (overweight)
- BP: 142-158/88-96 mm[Hg] (Stage 1 hypertension)
- Heart Rate: 78-88 bpm
- Temperature: 36.5-37.1Â°C

**4 Comorbid Conditions:**

- Malignant neoplasm of breast (primary diagnosis)
- Essential hypertension
- Hypothyroidism
- Osteopenia

**Diagnostic Imaging:**

- **Mammogram:** Right breast mass, 2.5cm irregular margins, BI-RADS 5 (highly suspicious)
- **Breast Ultrasound:** Hypoechoic solid mass, posterior acoustic shadowing
- **Core Needle Biopsy:** Invasive ductal carcinoma, Grade 2
  - ER positive (90%)
  - PR positive (75%)
  - HER2 negative
  - Ki-67 20%

**Initial Tumor Markers:**

- **CA 15-3: 72-78 U/mL** (elevated - normal <31 U/mL)
- **CEA: 8.2-8.8 ng/mL** (elevated - normal <3.0 ng/mL)

**Baseline Labs:**

- **CBC Panel:** WBC 7.2-8.5, Hgb 13.5-14.5, Platelets 210-280
- **CMP Panel:** Glucose 92-105, Creatinine 0.85-1.05, Normal liver function

**Medications Started:**

- Lisinopril 10mg (hypertension)
- Levothyroxine 50mcg (hypothyroidism)

#### Demo query examples:

- "What type of breast cancer?" â†’ ER+/PR+/HER2- invasive ductal carcinoma âœ…
- "Initial CA 15-3 level?" â†’ 75 U/mL âœ…
- "BI-RADS category?" â†’ BI-RADS 5 âœ…

---

### Phase 2: Staging Workup (Week 1) - Determining Extent of Disease

**The Story:** Oncology consultation. Staging studies ordered to rule out metastatic disease.

**Imaging Studies:**

- **CT Chest/Abdomen/Pelvis:** No evidence of distant metastases, no lymphadenopathy beyond axilla
- **Bone Scan:** No evidence of osseous metastases

**Cancer Care Plan Initiated:**

- Cancer care education
- Nutritional support
- Cancer surveillance protocols

**Clinical Stage:** T2N1M0 - Stage IIB

#### Demo query examples:

- "Is there metastatic disease?" â†’ No, M0 âœ…
- "Cancer stage?" â†’ Stage IIB âœ…
- "CT scan results?" â†’ No distant metastases âœ…

---

### Phase 3: Surgical Treatment (Week 3) - Lumpectomy & Sentinel Node Biopsy

**The Story:** Inpatient admission for breast-conserving surgery.

**Procedures:**

- **Lumpectomy:** 2.8cm invasive ductal carcinoma excised, margins negative (>2mm)
- **Sentinel Lymph Node Biopsy:** 1 of 3 sentinel nodes positive for metastases

**Pathology:**

- pT2 (2.8cm)
- pN1 (1/3 nodes positive)
- Stage IIB confirmed

#### Demo query examples:

- "Surgical margins?" â†’ Negative, >2mm âœ…
- "Lymph node status?" â†’ 1 of 3 positive âœ…
- "What surgery was performed?" â†’ Lumpectomy with sentinel node biopsy âœ…

---

### Phase 4: Post-Operative Recovery (Week 5) - Surgical Follow-up

**The Story:** Wound healing well. Patient ready for adjuvant chemotherapy.

**Vital Signs:**

- Weight: 66-70 kg (slight post-operative weight loss)
- BP: 138-152/85-93 mm[Hg]

**Tumor Markers (Post-Surgery):**

- **CA 15-3: 58-64 U/mL** (â†“18% from baseline - tumor burden reduced)
- **CEA: 6.8-7.4 ng/mL** (â†“15% from baseline)

**Pain Management Care Plan:**

- Pain education
- Pain monitoring protocols

**Medication Added:**

- Gabapentin 300mg (neuropathic pain management)

#### Demo query examples:

- "CA 15-3 trend?" â†’ 75 â†’ 61 U/mL (decreasing) âœ…
- "Post-op pain management?" â†’ Gabapentin prescribed âœ…

---

### Phase 5: Chemotherapy Cycle 1 (Week 8) - Starting Systemic Treatment

**The Story:** Begins AC-T chemotherapy regimen (Adriamycin/Cytoxan followed by Taxol). First cycle well-tolerated.

**Procedure:**

- Chemotherapy infusion (2-3 hours)

**Vital Signs:**

- Weight: 64-68 kg (chemotherapy-related weight loss beginning)

**Labs:**

- **CBC Panel:** WBC 5.2-6.5 (mild leukopenia), Hgb 11.5-12.8 (anemia developing), Platelets 180-230
- **CA 15-3: 45-52 U/mL** (â†“33% from baseline - responding to chemo)

**Supportive Medications:**

- Ondansetron 8mg (anti-nausea)
- Dexamethasone 4mg (anti-inflammatory, appetite)

#### Demo query examples:

- "Chemotherapy regimen?" â†’ AC-T protocol âœ…
- "Is CA 15-3 responding?" â†’ Yes, down to 48 U/mL âœ…
- "Side effect management?" â†’ Ondansetron, dexamethasone âœ…

---

### Phase 6: Chemotherapy Cycle 2 (Week 11) - Continued Treatment

**The Story:** Second chemotherapy cycle. Experiencing fatigue, mild nausea. Counts recovering adequately between cycles.

**Labs:**

- **CBC Panel:** WBC 4.5-5.8 (persistent mild leukopenia), Hgb 10.8-12.2, Platelets 165-210
- **CA 15-3: 32-38 U/mL** (â†“55% from baseline - excellent response)

#### Demo query examples:

- "Blood count trends?" â†’ Mild cytopenias, recovering between cycles âœ…
- "CA 15-3 at cycle 2?" â†’ 35 U/mL (continuing to decrease) âœ…

---

### Phase 7: Mid-Treatment Restaging (Week 14) - Response Assessment

**The Story:** Halfway through chemotherapy. Imaging to assess treatment response.

**Imaging:**

- **CT Chest/Abdomen/Pelvis:** No new lesions, stable post-surgical changes
- **Mammogram:** Surgical bed stable, no recurrence

**Tumor Markers:**

- **CEA: 4.8-5.4 ng/mL** (â†“37% from baseline)

#### Demo query examples:

- "Mid-treatment imaging?" â†’ Stable, no progression âœ…
- "CEA trend?" â†’ Decreasing from 8.5 to 5.1 ng/mL âœ…

---

### Phase 8: Post-Chemotherapy Surveillance (Month 6) - Completion of Acute Treatment

**The Story:** Completed 6 cycles of chemotherapy. Now completed 30 fractions of radiation therapy. Starting endocrine therapy.

**Vital Signs:**

- Weight: 66-70 kg (weight recovering)

**Tumor Markers:**

- **CA 15-3: 18-22 U/mL** (â†“73% from baseline - near normal range)
- **CEA: 2.8-3.4 ng/mL** (â†“63% from baseline - normal range)

**Imaging:**

- **Mammogram:** No evidence of recurrence

**Medication - Adjuvant Endocrine Therapy:**

- **Tamoxifen 20mg daily** (5-year planned duration for ER+ breast cancer)

#### Demo query examples:

- "Post-treatment CA 15-3?" â†’ 20 U/mL (normalized) âœ…
- "What endocrine therapy?" â†’ Tamoxifen 20mg daily âœ…
- "Mammogram findings?" â†’ No recurrence âœ…

---

### Phase 9: One-Year Surveillance (Month 12) - First Annual Follow-up

**The Story:** One year from diagnosis. Patient feeling well, back to normal activities. No evidence of disease.

**Tumor Markers:**

- **CA 15-3: 12-16 U/mL** (normal range maintained)

**Imaging:**

- **Annual Surveillance Mammogram:** No recurrence, stable post-surgical/radiation changes

**Labs:**

- **CBC Panel:** WBC 6.5-7.8, Hgb 12.8-13.8 (counts fully recovered)

#### Demo query examples:

- "One-year CA 15-3?" â†’ 14 U/mL âœ…
- "Any recurrence?" â†’ No evidence of disease âœ…
- "Blood counts recovered?" â†’ Yes, all normal âœ…

---

## Clinical Outcomes Summary

### Tumor Marker Trends (Demonstrates Treatment Response):

- **CA 15-3 Trend:** 75 â†’ 61 â†’ 48 â†’ 35 â†’ 20 â†’ 14 U/mL (81% reduction, normalized)
- **CEA Trend:** 8.5 â†’ 7.1 â†’ 5.1 â†’ 3.1 â†’ 2.1 ng/mL (75% reduction, normalized)

### Treatment Timeline:

- **Week 0:** Diagnosis (Stage IIB, ER+/PR+/HER2-)
- **Week 3:** Surgery (Lumpectomy + sentinel node biopsy)
- **Weeks 8-20:** Chemotherapy (6 cycles AC-T)
- **Weeks 21-26:** Radiation therapy (30 fractions - not explicitly modeled)
- **Month 6+:** Adjuvant endocrine therapy (Tamoxifen 5 years)

### Hematologic Impact of Chemotherapy:

- **WBC:** 7.5 â†’ 5.5 â†’ 4.8 â†’ 6.8 (mild leukopenia during treatment, recovery)
- **Hemoglobin:** 14.0 â†’ 12.0 â†’ 11.5 â†’ 13.3 (chemotherapy-induced anemia, recovery)
- **Platelets:** 245 â†’ 205 â†’ 185 â†’ normalized (mild thrombocytopenia)

### Weight Changes:

- **Baseline:** 70kg
- **Nadir (during chemo):** 64-66kg (6kg loss)
- **Recovery:** 68kg (partial recovery)

---

## Resource Volume (Tests All Query Types)

### DiagnosticReports:

- 6 CA 15-3 panels (dr_subtype for tumor marker queries)
- 4 CEA panels (dr_subtype for tumor marker queries)
- 4 CBC panels (dr_subtype:drCBC)
- 1 CMP panel (dr_subtype:drCMP)

### Observations:

- 20+ vital signs observations
- 10 tumor marker observations (CA 15-3, CEA)
- 30+ lab observations within panels

### ImagingStudies:

- 4 Mammograms (diagnostic, staging, surveillance)
- 2 Breast ultrasounds
- 2 CT Chest/Abdomen/Pelvis scans
- 1 Bone scan

### Procedures:

- 1 Core needle biopsy
- 1 Lumpectomy
- 1 Sentinel lymph node biopsy
- 2 Chemotherapy administrations (represents 6 cycles)
- 1 Physical examination

### Medications:

- 7 unique medication orders (Lisinopril, Levothyroxine, Gabapentin, Ondansetron, Dexamethasone, Tamoxifen)

### Conditions:

- 4 conditions (Breast cancer, Hypertension, Hypothyroidism, Osteopenia)

### CarePlans:

- 2 comprehensive care plans (Cancer treatment, Pain management)

### Encounters:

- 9 encounters spanning 12 months (diagnosis, staging, surgery, post-op, 2 chemo visits, restaging, 2 surveillance)

---

## TRAIS Query Testing Use Cases

### Oncology-Specific Queries:

- âœ… "What type of breast cancer?" â†’ ER+/PR+/HER2- invasive ductal carcinoma, Stage IIB
- âœ… "Cancer stage?" â†’ Stage IIB (T2N1M0)
- âœ… "Lymph node involvement?" â†’ 1 of 3 sentinel nodes positive
- âœ… "Surgical margins?" â†’ Negative, >2mm clearance
- âœ… "Hormone receptor status?" â†’ ER+ 90%, PR+ 75%, HER2 negative

### Tumor Marker Trending:

- âœ… "CA 15-3 trend?" â†’ 75 â†’ 61 â†’ 48 â†’ 35 â†’ 20 â†’ 14 U/mL
- âœ… "Recent CA 15-3?" â†’ 14 U/mL (normalized)
- âœ… "Is CA 15-3 responding to treatment?" â†’ Yes, 81% reduction
- âœ… "CEA levels?" â†’ 8.5 â†’ 3.1 ng/mL (normalized)
- âœ… "Last 5 tumor markers?" â†’ Shows both CA 15-3 and CEA trends

### Treatment Queries:

- âœ… "What chemotherapy was given?" â†’ AC-T regimen (Adriamycin/Cytoxan/Taxol)
- âœ… "What surgery was performed?" â†’ Lumpectomy with sentinel node biopsy
- âœ… "Current cancer medications?" â†’ Tamoxifen 20mg daily
- âœ… "Side effect management?" â†’ Ondansetron (nausea), Dexamethasone, Gabapentin (pain)
- âœ… "Radiation therapy?" â†’ Completed 30 fractions (referenced in narrative)

### Imaging & Diagnostic Queries:

- âœ… "Mammogram results?" â†’ Multiple studies from diagnostic to surveillance
- âœ… "Bone scan findings?" â†’ No osseous metastases
- âœ… "CT scan results?" â†’ No distant metastases, stable
- âœ… "Latest imaging?" â†’ Surveillance mammogram at 12 months, no recurrence
- âœ… "BI-RADS category?" â†’ BI-RADS 5 (initial diagnostic mammogram)

### Hematologic/Side Effect Queries:

- âœ… "Blood count trends during chemo?" â†’ Shows cytopenias and recovery
- âœ… "Is patient anemic?" â†’ Yes during chemo (Hgb 11.5), recovered to 13.3
- âœ… "White blood cell count?" â†’ Mild leukopenia during chemo, recovered
- âœ… "Platelet count?" â†’ Mild thrombocytopenia during chemo

### Survivorship & Follow-up:

- âœ… "Any recurrence?" â†’ No evidence of disease at 12 months
- âœ… "Surveillance plan?" â†’ Annual mammograms, periodic tumor markers
- âœ… "Long-term medications?" â†’ Tamoxifen 5 years planned
- âœ… "Patient status?" â†’ In remission, on surveillance

### Comorbidity Management:

- âœ… "Other medical conditions?" â†’ Hypertension, hypothyroidism, osteopenia
- âœ… "Blood pressure control?" â†’ On lisinopril, BP improved
- âœ… "Thyroid medication?" â†’ Levothyroxine 50mcg

---

## Technical Implementation Notes

- âœ… **All DiagnosticReports have empty observations arrays** - Observations created separately
- âœ… **Oncology-specific LOINC codes** - CA 15-3 (6875-9), CEA (2039-6)
- âœ… **Realistic tumor marker values** - Elevated at diagnosis, trending down with treatment
- âœ… **Clinically accurate timeline** - 12 months from diagnosis through early survivorship
- âœ… **Proper cancer staging** - TNM staging (T2N1M0 = Stage IIB)
- âœ… **Receptor status** - ER+/PR+/HER2- subtype (most common breast cancer)
- âœ… **Treatment sequence** - Surgery â†’ Chemo â†’ Radiation â†’ Endocrine therapy (standard of care)
- âœ… **Chemotherapy side effects** - Cytopenias, weight loss, need for supportive meds
- âœ… **Medication rationale** - All meds linked to conditions or symptoms
- âœ… **Imaging modalities** - Mammography (MG), Ultrasound (US), CT, Nuclear Medicine (bone scan)

---

## Module Details

**File:** `golden_patient_3.json`
**States:** 94
**Synthea Command:** `./run_synthea -p 1 -g F -a 55-65`
**Expected Output:** 150+ FHIR resources across 15+ resource types
**Testing Focus:** Oncology queries, tumor marker trending, cancer staging, treatment timelines, imaging, survivorship

---

## Clinical Significance

This patient demonstrates a **complete breast cancer journey** from diagnosis through early survivorship:

1. **Realistic disease course** - Stage IIB breast cancer with standard treatment
2. **Tumor marker utility** - CA 15-3 and CEA trending shows treatment response
3. **Multimodal imaging** - Mammography, ultrasound, CT, bone scan
4. **Comprehensive treatment** - Surgery, chemotherapy, radiation, endocrine therapy
5. **Side effect management** - Realistic cytopenias, supportive medications
6. **Survivorship care** - Transition to surveillance and long-term endocrine therapy

Perfect for testing TRAIS capabilities with:

- Cancer-specific terminology and staging
- Longitudinal tumor marker trending
- Treatment response assessment
- Imaging interpretation
- Survivorship queries
